as 02-14-2025 9:39am EST
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Founded: | 2017 | Country: | Israel |
Employees: | N/A | City: | N/A |
Market Cap: | 17.8M | IPO Year: | 2021 |
Target Price: | N/A | AVG Volume (30 days): | 166.2K |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.66 | EPS Growth: | N/A |
52 Week Low/High: | $0.51 - $2.33 | Next Earning Date: | 04-04-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
NRSN Breaking Stock News: Dive into NRSN Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
PR Newswire
a month ago
MT Newswires
2 months ago
MT Newswires
2 months ago
PR Newswire
2 months ago
PR Newswire
2 months ago
PR Newswire
2 months ago
MT Newswires
2 months ago
The information presented on this page, "NRSN NeuroSense Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.